BACKGROUND Mineralocorticoid receptor antagonists (MRA) improve outcome in the setting of post-myocardial
High aldosterone plasma levels early after STEMI or NSTEMI are associated with mortality, sudden cardiac death, and HF (5) (6) (7) (8) . Experimental studies have shown that early MRA administration after myocardial infarction (MI) could improve myocardial healing (9) as well as both electrical and structural remodeling (10) . Small-sized studies have also reported benefits of MRA therapy initiated early after MI in the prevention of LV remodeling (11, 12) and lifethreatening arrhythmia (13, 14) .
Whether Such patients were nevertheless kept in the intention-to-treat analysis.
Patients were followed for 6 months after randomization and visits after hospital discharge included measurements of LV ejection fraction. Spironolactone was suspended during follow-up if plasma potassium concentrations were >5.5 mmol/l
and/or plasma creatinine levels were >220 mmol/l -1
on any blood sample whether protocol-specified or not. The treatment was reintroduced after normalization of potassium and creatinine levels if the cause was considered reversible. The study Premature discontinuation of study treatment, acute renal failure, and hyperkalemia were closely monitored. All outcomes were adjudicated in a blinded manner by an independent adjudication committee.
STATISTICAL ANALYSIS. We hypothesized that the 6-month rate of the primary endpoint would be 20%
in the standard therapy alone arm. With a sample size 
RESULTS
Between February 2010 and January 2014, a total of 1,622 patients consented and were randomly assigned Death from any cause ( Figure 3A) , as well as all other components of the primary outcome ( Table 2) , did not differ between the 2 groups. All secondary outcomes occurred with comparable rates in the 2 groups ( Table 2) .
The results were consistent among all pre-specified subgroups with respect to the primary outcome Per the Kaplan-Meier estimate, there was no difference between the arms in terms of the primary outcome, which was a composite of death, resuscitated cardiac arrest, significant ventricular arrhythmia, indication for implantable defibrillator, or new or worsening heart failure.
CI ¼ confidence interval; MRA ¼ mineralocorticoid receptor antagonist. Values are n (%).
CI ¼ confidence interval; HF ¼ heart failure; HR ¼ hazard ratio; other abbreviations as in Table 1 .
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A P R I L 2 6 , 2 0 1 6 : 1 9 1 7 -2 7 The type of myocardial infarction in regard to ST-segment elevation significantly impacted mortality. Abbreviations as in Figure 4 .
FIGURE 4 Subgroup
JACC VOL. 67, NO. 16, 2016 Beygui The benefit observed was apparently driven by the group of patients treated earlier (i.e., 3 to 7 days) (22) .
This finding is consistent with other studies reporting high aldosterone plasma levels early after MI (23, 24) and the relationship of these levels with clinical outcomes (5-7) . The recent REMINDER study also reported encouraging results with eplerenone in lowrisk STEMI patients, although the benefit was observed more on B-type natriuretic peptide levels than clinical outcomes (4).
The ALBATROSS study recruited a broad population of MI representing the general population hospitalized for this condition, rarely associated with concomitant HF or severe LV dysfunction. These patients were enrolled early then received IV canrenoate for rapid mineralocorticoid receptor blockade and they had good adherence to spironolactone over 6 months. However, we were unable to show a benefit of early and sustained MRA therapy in this MI population, which cannot be compared to the much higher risk EPHESUS trial population.
Although the STEMI population in our study was at much higher risk than the REMINDER (4) Values are n (%).
Abbreviations as in Tables 1 and 2. ventricular arrhythmias were considered significant only if a therapy was required for their treatment (i.e., electrical cardioversion or antiarrhythmic therapy).
Hence, the effect of MRA use on global rates of ventricular arrhythmia post-MI cannot be assessed by our study.
The ALBATROSS study also highlights the relative safety of the MRA regimen used. Although the rates of hyperkalemia were higher in the MRA group than in the control group, they remained lower than previously reported (3,4) and the rates of adverse events were equally distributed between the 2 study groups (data not shown). lower risk than expected with a possible selection bias.
Our trial was not adequately powered to examine hard clinical outcomes. Although the study would have
been adequately powered to demonstrate a mortality reduction in STEMI patients, randomization was not stratified on the type of ACS and our finding should be considered hypothesis generating at this point. Larger studies are needed to re-examine the effect of MRA therapy on such outcomes in STEMI patients. With respect to the multiple testing in the subgroup analyses, the risk of type I error may be important, both for the primary and the mortality endpoints, and the analysis should be considered as only exploratory.
Finally, the present MRA regimen used potassium canrenoate and spironolactone, and our results may not be fully extrapolated to eplerenone.
CONCLUSIONS
The ALBATROSS trial failed to show a benefit of an 
